INTRODUCTION
In the absence of a cure, treatment of Crohn's disease (CD) is directed at induction and maintenance of remission with medical therapy. 1 The medical armamentarium for the treatment of CD has expanded in the past two decades and biological agents targeting tumour necrosis factor (TNF) alpha have become the mainstay of treatment for moderate-to-severe luminal and fistulising CD. [2] [3] [4] [5] Despite the advent of anti-TNF therapy, 50% of CD patients require surgery within 10 years of diagnosis and 25% will require a second operation within 10 years of their first surgery. 6, 7 Large randomised controlled trials (RCTs) have demonstrated the efficacy of anti-TNF agents for the induction and maintenance of clinical remission, but 40% of CD patients are primary nonresponders to induction therapy. 8 Furthermore, up to half of primary responders will eventually lose response or develop adverse events (AEs) to treatment. 9 Patients with secondary loss of response typically have a complex and aggressive disease phenotype and are less likely to benefit from switching to a second TNF antagonist. 10, 11 This cohort of patients is challenging to treat, with limited therapeutic options. Non-TNF mediated pathways of inflammation may be implicated in anti-TNF nonresponders. Specifically, interleukins (IL)-12 and -23 may play a key role in the pathogenesis of CD-related T-lymphocyte dysregulation. In murine models, IL-12 and IL-23 stimulate a robust Th1 and Th17 inflammatory response. 12 Furthermore, genome-wide association studies of CD patients have identified polymorphisms in genes encoding the IL-12 p35 and IL-12/23 p40 common subunits. 13 Ustekinumab is a fully human IgG 1j monoclonal antibody blocking IL-12 and IL-23 via their common p40 subunit. In a large phase IIb RCT of 526 CD patients (CERTIFI Crohn's Evaluation of Response to Ustekinumab AntiInterleukin-12/23 for Induction), Sandborn et al. found ustekinumab superior to placebo for achieving clinical response 14 and further supportive evidence from the phase III UNITI-1, UNITI-2 and IM-UNITI trials have recently been published. 15 Ustekinumab has recently been approved by the United States Food and Drug Administration, European Medicines Agency, and Health Canada for treatment of moderate-to-severely active CD. Gastroenterologists have previously accessed ustekinumab through compassionate release programs or clinical trials. Few studies have described the open-label experience with ustekinumab in CD and currently published series are limited by small sample size, lack of objectively defined response, and short duration of follow-up. [16] [17] [18] [19] Here, we aim to describe the real world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in a large multicentre cohort of CD patients failing anti-TNF therapy. Second, we assess predictors of response and the safety profile of ustekinumab.
MATERIALS AND METHODS

Study design and patient population
A retrospective observational cohort study was performed at two academic tertiary care institutions at the University of Calgary, Calgary, Canada and the University of Alberta, Edmonton, Canada. Consecutive adult patients (≥18 years) receiving ustekinumab between January 1, 2011 and July 1, 2016 were identified. Inclusion criteria included: (i) endoscopically and histologically confirmed CD; (ii) failure of conventional medical therapy (corticosteroid refractory or dependent disease, failure or intolerance of immunomodulators, anti-TNF agents or other biologics) and (iii) received at least one dose of subcutaneous or intravenous ustekinumab. Patients receiving intravenous induction as part of clinical trial but were confirmed upon unblinding to have received ustekinumab instead of placebo, and who were subsequently advanced onto open-label ustekinumab were eligible for inclusion.
Outcomes and definitions
The primary objective of this study was to define the proportion of CD patients achieving clinical response and remission with ustekinumab at 3, 6 and 12 months.
Response and remission were defined in accordance with the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) definitions. 20 Clinical response was defined by a compos- For patients with active perianal fistulising disease at ustekinumab induction, additional definitions of clinical response and remission also had to be achieved. Fistula response was defined by a reduction in the number of draining fistulas by 50% compared to baseline, as assessed by physical examination, without the need for surgical interventions including examination under anaesthesia, fistulotomy or seton placement. Clinical remission in this cohort was defined by complete absence of fistula drainage on patient history and closure of all fistulas on physical examination.
The secondary objective was to define the proportion of CD patients achieving objective endoscopic or radiographic response and remission to ustekinumab at 6 and 12 months, as assessed by ileocolonoscopy, contrast-enhanced ultrasound or CT/MR enterography. Endoscopic response was defined by an improvement in mucosal inflammation compared to baseline with at minimum, resolution of deep ulcerations. Endoscopic remission was defined by achievement of complete mucosal normalisation, except for residual apthous ulcers. Radiographic response was defined by improvement in bowel wall thickness, inflammatory fat, mural blood flow and hyperenhancement compared to baseline imaging by physician global assessment. 22 Radiographic remission was defined by complete normalisation of inflammatory parameters on cross-sectional imaging. Response to ustekinumab for patients with perianal disease was defined by complete fistula healing on dedicated pelvic contrast-enhanced ultrasound or pelvic MRI.
Total follow-up time was determined from the date of first ustekinumab dose to the last date of ustekinumab administration or ustekinumab discontinuation. In determining the proportion of patients achieving clinical and objective response at 3, 6 and 12 months, patients who had failed ustekinumab and discontinued therapy were classified as nonresponders. Patients responding to treatment but with inadequate follow-up time were considered censored cases but not included in determining overall response rate at specific time points. For example, a patient with only 10-months follow-up but who was responding to treatment would have contributed to the 6-month analysis, but not the 12-month analysis.
Data collection
Comprehensive chart review was performed from two sources: (i) physician office-based electronic and paper charts (including clinic letters, nursing and patient correspondence and out-patient prescriptions) and (ii) the region-wide electronic health care database used at both recruitment centres (including in-patient and out-patient laboratory investigations, hospital discharge summaries, and diagnostic imaging, pathology, surgical and endoscopy reports).
Baseline data collected included gender, age, weight, smoking status, disease duration, disease phenotype (by the Montreal Classification for CD 23 ), previous and concurrent CD treatments (including immunomodulators, anti-TNF therapy, other biologics and previous surgery), clinical and serologic measures of disease activity at ustekinumab induction (C-reactive protein, HBI), and ustekinumab induction and maintenance dosing. Patients were stratified by method of induction (intravenous vs. subcutaneous) and induction dose within the first 4 weeks of treatment adjusted for weight (rounded to nearest 3 mg/kg vs. 6 mg/kg). Induction dose was adjusted for method of administration assuming a linear bioavailability correlation factor of 0.6 for subcutaneous compared to intravenous dosing. 24 
Statistical analysis
Baseline characteristics were analysed with standard descriptive statistics. Medians with interquartile ranges (IQR) were calculated for continuous data and proportions were assessed for categorical data. The proportion of ustekinumab responders at each time point was compared using the Pearson chi-squared test. Univariate and multivariate logistic regression analyses were performed to identify factors predictive of clinical and objective response at 6 months, expressed as odds ratios with 95% confidence intervals. Variables for the univariate analysis were chosen a priori, including gender, body weight, smoking status, disease activity, disease phenotype, medication use and ustekinumab dosing. Variables with a P < 0.20 were included in the multivariate analysis. The Kaplan-Meier method was used to assess ustekinumab drug continuation over time.
Statistical analysis was performed using SPSS 24.0 statistical software (IBM Corporation; Armonk, NY, USA). This study was approved by the Human Research Ethics Board at both the University of Calgary and the University of Alberta. This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations.
RESULTS
Baseline patient characteristics
Patient demographics are summarised in Table 1 . One hundred and sixty-seven CD patients met inclusion criteria and were followed up for a median of 45.6 weeks (IQR: 24.4-88.9 weeks). Most patients had ileocolonic CD (83/167, 49.7%) with inflammatory (65/167, 38.9%) disease phenotype. A total of 66.5% (111/167) of patients had previous CD-related bowel resection. Almost all patients had previously been exposed to biological therapy and 117 patients (70.1%) had failed at least two biological therapies. Eight patients had previous exposure to vedolizumab, 10 patients had previous exposure to golimumab (an anti-TNF agent but used off-label for Crohn's disease), and four patients had previous 
Ustekinumab induction and maintenance dosing
Multiple induction regimens were used, ranging from 90 mg to 630 mg administered within the first 4 weeks of therapy over a median of 2.0 doses given either intravenously or subcutaneously (range 1-4). 88.6% (148/167) of patients received subcutaneous induction dosing. The most common subcutaneous induction regimens were 90 mg administered on weeks 0 and 4 (n = 52, 35.1%), 90 mg administered on weeks 0, 1 and 2 (n = 53, 35.8%), and 270 mg administered week 0 + 180 mg administered weeks 1 and 2 (n = 11, 7.4%). Complete subcutaneous induction dosing regimens are available in Table S1 . Initial maintenance dosing was 90 mg subcutaneous every 8 weeks for 138 patients (82.6%) and every 12 weeks for 26 patients (15.6%). Only three patients received ustekinumab 90 mg subcutaneously every 6 weeks as the initial maintenance regimen.
Clinical response and remission with ustekinumab Steroid-free clinical response to ustekinumab therapy is summarised in Figure 1 . At 3 months, clinical response was achieved by 38.9% of patients (65/167 patients). Numerical but not statistically significant differences in clinical response rates at 3 months among patients receiving 6 mg/kg compared to 3 mg/kg induction (Figure 2a, 43 .5% vs. 36.2%, P = 0.35) and among patients receiving intravenous compared to subcutaneous induction (Figure 2b , 57.9% vs. 36.5%, P = 0.07) were observed. Twenty-five patients (15.0%) achieved clinical remission within 3 months of treatment.
A total of 151 patients had follow-up at 6 months. Within this cohort, 60.3% (91/151) had achieved steroidfree clinical response and 25.2% (38/151) had achieved clinical remission. Among 102 nonresponders at 3 months, 33 patients (32.4%) subsequently achieved clinical response at 6 months. Among patients who were followed up for 12 months or discontinued ustekinumab prior to 12 months, 59.5% of patients (66/111) maintained steroid-free clinical response and 31 patients (27.9%) were in clinical remission.
Among patients with fistulising disease, clinical response rate was 48.9% (22/45) and remission rate was 26.7% (12/45) at the end of follow-up. No differences in 12-month or end of follow-up response were observed between patients receiving maintenance therapy every 8 weeks compared to every 12 weeks (Figure 2c ).
Objective response and remission with ustekinumab At the end of follow-up, 141 patients in the cohort (84.4%) had objective evaluation of disease: 92 patients had direct endoscopic visualisation and 49 patients had radiographic assessment. Approximately half of patients achieved objective response at 6 and 12 months (Figure 1 ) and approximately one quarter of patients were in objectively defined remission. In subgroup analysis of patients undergoing ileocolonoscopy, endoscopic response and remission rates at the end of follow-up were 55.4% (51/92) and 27.2% (25/92) respectively. At the end of follow-up, 53.2% (75/141) of patients had achieved an objective response to ustekinumab, with no difference in the proportion of endoscopic and radiographic responders (55.4% vs. 44.6%, P = 0.46).
In 45 CD patients with perianal disease at the time of ustekinumab induction, 14 patients (31.1%) achieved complete healing as demonstrated by pelvic MR or dedicated pelvic contrast-enhanced ultrasound. The impact of ustekinumab therapy on C-reactive protein is summarised in Figure S1 and 
Safety profile
Fifty-three patients (31.1%) experienced an AE while on ustekinumab ( Table 3 ). The most common AEs were infections (20/167, 12.0%), typically mild upper respiratory tract or skin/soft tissue infections. Arthralgia was also common (19/167, 11.4%). Serious AEs requiring hospitalisation or ustekinumab discontinuation occurred in 11 patients (6.6%): one patient was hospitalised with a respiratory tract infection, one patient was hospitalised with pancreatitis, and eight patients (4.8%) required drug discontinuation due to intolerable AEs (three patients with injection reactions, two patients with arthralgia, two patients with fatigue and one patient due to dental abscess). No cases of malignancy, tuberculosis or direct deaths related to ustekinumab occurred. One 86-year-old patient in the cohort died from complications of preexisting cardiac and pulmonary comorbidity, but it was felt unlikely to be directly related to CD or ustekinumab therapy. 
DISCUSSION
The management of moderate-to-severe CD has been revolutionised by the introduction of biological agents, predominantly targeting TNF-a. However, there is a pressing need for novel therapeutic options for patients with aggressive, complex phenotype disease failing anti-TNF therapy. 10 In this large, multicentre cohort study, we examined the short-and long-term steroid-free clinical, endoscopic and radiographic response and remission outcomes with ustekinumab in a cohort of patients with moderate-to-severe CD, in whom 70% had failed multiple biological agents and two-thirds had experienced surgery. We demonstrate that over half of patients achieved a steroid-free clinical response, but this could be delayed up to 6 months after induction. In addition to clinical benefit, over 50% of patients achieved endoscopic or radiographic response and over a quarter of patients achieved objectively defined remission. Findings from the CERTIFI phase IIB RCT provided early support for the role of ustekinumab in CD. In this study of 526 CD patients with previous failure to anti-TNF therapy randomised to ustekinumab (1, 3 or 6 mg/kg IV) or placebo, 39.7% of patients receiving ustekinumab 6 mg/ kg induction therapy were able to achieve clinical response. This was significantly higher than the placebo response rate of 23.5% (P = 0.005).
14 These results were further corroborated in the recently published phase III UNITI-1 and UNITI-2 RCTs, where clinical response rates of 33.7% and 55.5%, respectively, were observed at 6 weeks. 15 Observational evidence from open-label cohorts suggests that real-life efficacy of ustekinumab may be better In this multicentre cohort of European CD patients treated with ustekinumab, a 3-month response rate of 65% is reported. 19 Similar findings have been reported in openlabel cohorts from Spain and Canada. 16, 25 Strengths of our cohort in comparison to previously published experiences include the more robust sample size, longer duration of follow-up, extensive evaluation of different dosing regimens and routes of administration, and objective evaluation of response in nearly 85% of patients. The proportion of patients achieving response to ustekinumab appears to increase over time: in our cohort, 33 patients who did not achieve 3-month clinical response achieved clinical response by 6 months. Similarly, in the CERTIFI trial, 69.4% of patients receiving ustekinumab achieved clinical response by week 22 compared to only 39.7% at week 6, suggesting there may be a delayed clinical response to induction. 14 We hypothesise this delay may relate to the mechanisms by which ustekinumab downregulates CD-related inflammation. Ustekinumab-induced IL-12/23 blockade results in modulation of T-cell differentiation and then subsequently, decreased Th1 and Th17 proinflammatory cytokine production. This 'upstream' immune process may delay immediate clinical benefit compared to the rapid improvement seen in patients treated with anti-TNF therapy directly targeting 'downstream' inflammatory effectors. 26 In the GETAID cohort, Wils et al. reported that concomitant immunosuppression was a predictive factor of efficacy [multivariate odds ratio 5.43 (95% CI: 1.14 -25.77)]. 19 However, the confidence interval for this estimate was quite wide and only 15% of patients were treated with combination therapy. In our cohort, we aggressively used combination therapy: 73 patients starting ustekinumab were on concomitant methotrexate or azathioprine but we did not find a beneficial effect on multivariate analysis for induction response. This may be a reflection that patients selected for combination therapy have more aggressive underlying disease. Furthermore, the protective effect of concomitant immunosuppression on prevention of anti-drug antibody formation as seen with anti-TNF therapy 27 may not be as relevant for ustekinumab: indeed, in the IM-UNITI trial, antibodies developed in only 2.3% of patients as measured by a drug-tolerant assay.
15
A major strength of our current cohort is the extensive evaluation of objectively defined response by radiography or endoscopy in over 80% of patients. Endoscopic response was reported in 51.4% of patients by Battat et al. 28 and 76% of patients by Harris et al. 18 Objective response in our cohort was demonstrated in approximately 55% of patients: differences may result from inclusion of radiographic evaluation, which also allows for more accurate assessment of extraluminal disease. One limitation is that a validated endoscopic or radiographic scoring system could not be retrospectively applied due to the study design. Thus, as with previous cohorts, 18 we used global assessment of objective data to define response. However, we used very rigorous definitions of endoscopic and radiographic remission, closely reflecting mucosal healing and in accordance with the STRIDE recommendations that may contribute to lower observed remission rates compared to other open-label cohorts. 20 In the previously published open-label ustekinumab experience, patients have received highly variable induction and maintenance dosing, limiting the generalisability of results. The optimal dosing strategy for ustekinumab induction has not been elucidated. RCTs have not found a strong dose-related response to ustekinumab induction therapy, although it is important to note that differences in clinical response compared to placebo in the CERTIFI trial were only significant at a dose of 6 mg/kg.
14 In our cohort, we corrected for the effect of different dosing regimens by analysing cumulative induction dosing during the first 4 weeks of treatment adjusted to weight and linear bioavailability models. We also did not find a significant correlation with clinical or objective response by weight-adjusted induction dose, induction method (intravenous vs. subcutaneous) or initial maintenance dosing. However, we did not have access to ustekinumab serum concentrations during induction and future studies should evaluate the effect of serum drug concentrations on induction response. 28 Overall, we found ustekinumab to be a safe therapeutic option: 30% of patients in our cohort experienced an AE while on therapy, with most being infectious complications. However, serious AEs requiring drug discontinuation or hospitalisation were very rare. Safety of ustekinumab has also been well-evaluated in the psoriasis population; pooled results from 3117 patients treated with ustekinumab for psoriasis found an event rate of 1.19 serious infections per 100-patient-years exposure. 29 Although the dosing used in psoriasis is typically lower than doses used in CD, very few serious AEs to ustekinumab have been reported in RCTs and open-label cohorts of CD patients. [16] [17] [18] [19] There are several limitations to our study. Primarily, this was a retrospective evaluation. Due to study design, certain factors potentially affecting ustekinumab efficacy such as adherence to therapy could not be assessed. Second, retrospective analysis does not allow for strict protocolled assessment of response and HBI tends to bias against patients with noninflammatory disease phenotype. Also, due to variability in practice and reporting patterns, we could not use consistently standardised radiographic or endoscopic scoring criteria and objective response may be underestimated by selection bias against symptomatic responders. However, we employed strict definitions of clinical and objective response and remission, in accordance with the STRIDE recommendations. Even with these strict definitions, over 50% of patients achieved an objectively defined response. Standardised endoscopy scoring tools such as the Simple Endoscopic Score for Crohn's Disease are not validated for retrospective application: however, our definitions of endoscopic and radiographic response and remission are highly relevant in real-life clinical practice. Finally, there is heterogeneity in the study cohort with respect to route of induction drug administration. However, we doseadjusted patients receiving intravenous induction on the basis of bioavailability and in subgroup analysis, there were no differences in clinical or objective outcomes by route of administration. We did not exclude patients receiving intravenous induction because this is an approved induction regimen in some jurisdictions, including in Canada.
In conclusion, in this large, multicentre, observational cohort of CD patients failing multiple biological agents, ustekinumab was effective for achieving short-and longterm steroid-free clinical and objective endoscopic and radiographic response and remission outcomes. Treatment with ustekinumab was safe and this study adds substantially to the growing literature that ustekinumab is an effective therapeutic option in difficult-to-treat CD. To our knowledge, this is the largest nonrandomised experience with ustekinumab in CD presented to date. Future studies are required to determine the best methods for monitoring and optimising response to ustekinumab therapy and to decide the role of ustekinumab in relation to other biological therapies for the management of refractory CD.
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